BridgeBio LLC
NEWS
BridgeBio Pharma, Inc. has announced the pricing of its initial public offering of 20,500,000 shares of its common stock at a price to the public of $17.00 per share, as detailed in the company’s press release.
Two of this week’s biotech startup initial public offerings, BridgeBio and Adaptive Biotechnologies, have market values exceeding the magic $1 billion mark, and have recently launched initial public offerings (IPOs), but also increased their fundraising goals.
This week marked initial public offering news from six biopharma companies. Here’s a look.
BridgeBio stepped in to take over the drug and also launch a subsidiary, QED Therapeutics, to drive the development of infigratinib.
Venture capital is hopping, attracted to some of the past several years’ successes.
JOBS
IN THE PRESS